This shows that fracture cases are one of the problems in the Indonesian health sector. Types of fractures or fractures vary widely, as well as the cause. For each type of fracture, it requires prompt and appropriate treatment.
READ ALSO – Experts Are Confused How Can It Be? Lice Drugs Become Covid-19 Drugs in Indonesia
Mismanagement of orthopedic injuries can be fatal. One way to treat fractures is to do bone implants or bone grafts.
In the standard procedure of bone graft treatment, the use of commercialized bone graft products is gradually increasing. This is because the autogneous method, which is a bone graft method using bone tissue originating from within the body, often causes various complications, including complaints of pain in the implantation area.
In Indonesia, CGBIO, a company that specializes in regenerative medicine, recently introduced its bone implant product ‘NOVOSIS’, a bone replacement containing rhBMP-2, Recombinant Human Bone Morphogenetic Protein-2, and ‘Excelos Inject’, a replacement material. bone containing beta-tricalcium phosphate in the Indonesian market, brightening the prospects for the local bone graft market.
Team Leader of the Indonesian Business Department CGBIO Eric Aoh, described NOVOSIS as “NOVOSIS is rhBMP-2, the first in South Korea and the second in the world, applicable to spinal fusion and fractures of the upper and lower extremities.
The product rhBMP-2, a growth factor protein that helps stem cells in the body rapidly differentiate into bone cells, was incorporated into ceramic materials for bone replacement.” “Novosis has the same results as autogenous bone grafting, so it does not cause complications due to autogenous bone grafting,” he added.
Excelos Inject is a bone graft product made of spherical beta-tricalcium phosphate with tens of micrometers in size. It can be used to fill in areas of damaged bone, increasing ease of use, and it can be absorbed slowly over time to become completely new bone.” said Eric.
– .
